The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Open accessAbstract
INTRODUCTION: Diabetic macular oedema (DMO) is a complication of diabetic retinopathy that can result in vision loss. The disease can impact different spheres of a patient's life, including physical and psychological health, work, and activities of daily living, entailing an important use of healthcare and non-healthcare resources. This study aimed to estimate the socio-economic burden of DMO in Spain. METHODS: The burden of DMO was estimated from a societal perspective, per patient, year of treatment since diagnosis, and type of treatment. Four categories were considered: direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labour productivity losses (LPL), and intangible costs (IC) associated with loss of quality of life. Average annual costs were calculated by multiplying the resources used per patient by their corresponding unit price (or financial proxy). For a more accurate estimation, differences in resource use between treatments (intravitreal anti-vascular endothelial growth factor injections of ranibizumab or aflibercept, and intravitreal dexamethasone implants) and year since diagnosis (first, second, and third year or beyond) were considered and presented separately. The reference year for costs was 2021. RESULTS: The average annual costs of DMO in the first year of treatment after diagnosis was estimated at €18,774, €17,512, and €16,188 per patient treated with ranibizumab, aflibercept, and dexamethasone, respectively. This burden would be reduced to €15,783, €15,701, and €12,233 in the second year, and to €15,119, €15,043, and €12,790 in the third year, respectively. Diagnosis of DMO entails an additional one-off cost of €485. DHC accounted for the greatest proportion of total annual costs per patient, independent of the year, with LPL also making an important contribution to total costs. CONCLUSIONS: The socio-economic impact of DMO on patients, the healthcare system, and society at large is substantial. The constant increase in its prevalence accentuates the need for planning and implementation of healthcare strategies to prevent vision loss and reduce the socio-economic burden of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As for direct non-medical costs, reflecting the use of formal care, transportation and vision aids, they were estimated at $2,068 per patient per annum in the Spanish model-based study [55].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Informal care and intangible costs, such as the loss of quality of life and daily activities, were also estimated in the same study at $193 and $3,767 respectively [55].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More specifically, lower costs were reported in patients treated with a DEX implant ($11,607 per patient per annum), as opposed to anti-VEGF injections only ($16,159 per patient per annum).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In terms of productivity losses in patients, they were estimated in only two studies [55, 57]: one combining reduction in labour and working hours in their estimates ($6,903 per patient per annum) [55]; and the other focusing on cost of temporary and permanent occupational disability ($14,471 per patient per annum) [57].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045
Teo, Z. L., Tham, Y.-C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y., Lu, Y., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.027 · Cited by 2,420
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Economic Note: Cost of illness studies
Byford, S. (2000) · BMJ · doi:10.1136/bmj.320.7245.1335 · Cited by 318
Burden of illness of diabetic macular edema: literature review
Chen, E., Looman, M., Laouri, M., Gallagher, M., Van Nuys, K., Lakdawalla, D., & Fortuny, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.482503 · Cited by 158
Romero‐Aroca, P., Sagarra-Alamo, R., Marc, B.-B., Fernandez-Ballart, J. D., & Méndez-Marín, I. (2010) · Ophthalmic Epidemiology · doi:10.3109/09286586.2010.498661 · Cited by 119
Mitchell, P., Annemans, L., Gallagher, M., Hasan, R., Thomas, S. K., Gairy, K., Knudsen, M. S., & Konwea, H. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300726 · Cited by 89
Intravitreal Pharmacotherapies for Diabetic Macular Edema
Ehlers, J. P., Yeh, S., Maguire, M. G., Smith, J. R., Mruthyunjaya, P., Jain, N., Kim, L. A., Weng, C. Y., Flaxel, C. J., Schoenberger, S. D., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.07.009 · Cited by 82
Gonder, J. R., Walker, V. M., Barbeau, M., Zaour, N., Zachau, B. H., Hartje, J. R., & Li, R. (2014) · Journal of Ophthalmology · doi:10.1155/2014/939315 · Cited by 77
Moreno, E. G., Mateo‐Abad, M., García, L. O. D. R., Vrotsou, K., Pena, E. D. C., Sánchez, Á., Carazo, C. M., Ortiz, J. C. A., Portu, M. Á. R., Elorriaga, K. P., et al. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.10.001 · Cited by 66
Cited by
Jabbar, R. M., Al‐Jumaili, A. A., Alkhatib, N. S., & Jaafar, A. D. (2025) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riaf075 · Cited by 5
El-Badawi, K., Scrivens, B., Eke, O., Ismail, R., Kobayter, L., & Salvatore, S. (2025) · Clinical ophthalmology · doi:10.2147/opth.s513009 · Cited by 2
Jabbar, R. M., Al‐Jumaili, A. A., & Jaafar, A. D. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00717-0 · Cited by 2
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“…annual costs over three years following diagnosis were estimated and suggested a drop in treatment costs from 11.5% to 29% after the first year of patients initiating anti-VEGF injections only and of 47% after a first year of treatment with the anti-VEGFs injections/DEX implant combination [55].”
InfluentialEl-Badawi, K., Scrivens, B., Eke, O., Ismail, R., Kobayter, L., & Salvatore, S. (2024) · medRxiv · doi:10.1101/2024.12.13.24318978
Metadata
- Authors
- Ruiz-Moreno, J. M., Gámez Lechuga, M., Calvo, P., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Abraldes, M. J.
- Affiliations
- Hospital Universitario Miguel Servet (ES)
- Weber (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Corresponding author
- Merino, María
- Venue
- Ophthalmology and Therapy
- Published
- 2024-05-21
- Volume
- 13
- Issue
- 7
- Pages
- 1937-1953
- ISSN
- 2193-6528 (ISSN-L)
- 2193-8245
- PMC
- PMC11178718
- OpenAlex
- W4398156667
- Cited by
- 7
- References
- 30
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Ophthalmology and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Roche Farma S.A.
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- diabetic macular edema, socioeconomic burden, health care costs, direct healthcare costs, labour productivity loss, quality of life, ranibizumab, aflibercept, intravitreal dexamethasone implant, intravitreal anti-VEGF therapy, vision loss, Spain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain. https://app.cochat.ai/papers/10.1007/s40123-024-00959-2
- The paper
- Ruiz-Moreno, J. M., Gámez Lechuga, M., Calvo, P., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Abraldes, M. J. (2024). Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-024-00959-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.